Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006–2010): based on registry data from the Japanese Society of Pediatric Hematology
- 895 Downloads
Neither accurate incidence nor survival data for pediatric patients with hematological malignancies (HM) have been available in Japan to date. Incidence of patients under 20 years of age, who were diagnosed with HM from 2006 to 2010, and their two-year survival rate (2y-OS) were obtained from disease registry data maintained by the Japan Society of Pediatric Hematology (JSPH). A total of 5,287 cases of HM were identified during this period. Acute lymphoblastic leukemia (ALL, 46.6 %) showed the highest incidence, followed by acute myeloid leukemia (AML, 16.7 %), non-Hodgkin lymphoma (NHL, 11.9 %), and histiocytosis (11.8 %). ALL, AML and histiocytosis were common in younger patients aged 1–4, while NHL tended to occur more frequently in older patients aged 5–14. The 2y-OS of HM was 91.6 %, with that for the most common B-precursor ALL rising to 96.2 %. The 2y-OS for M3 AML, lymphoblastic-B-precursor or diffuse large B cell NHL, Hodgkin lymphoma, myeloproliferative disorders, and Langerhans cell histiocytosis was >95 %. There were no gender differences in prognosis, while infants (88.0 %) and adolescents aged 15–19 (90.6 %) tended toward a poorer prognosis. This is the first report to describe incidence and survival times from the nationwide JSPH disease registry. More precise data with longer follow-up is needed.
KeywordsHematological malignancies Children Registry data Survival
The survey on hematological malignancies incidence in Japan was conducted with contributions from the 187 institutions, described in Appendix 1. The authors thank deeply the members, especially Kaori Nagai, Kazumi Takeuchi, Maki Nishimura, and Midori Otomo of the Data Management Department of the NPO-OSCR, for their support in the management of the electronic or paper-based survey system and in the cleaning and tabulation of the registered data.
Conflict of interest
The authors have no financial relationship to declare.
- 1.The Research Program for the Treatment of Chronic Pediatric Diseases of Specified Categories: Department of Health Policy. Available from URL: http://www.nch.go.jp/policy/shoumann.htm. Accessed October, 2012.
- 2.Research group of the Treatment of Chronic Pediatric Diseases of Specified Categories. Available from URL: http://www.aiiku.or.jp/aiiku/mch/syoman/syo.html. Accessed October, 2012.
- 3.Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2012;42(2):139–47.PubMedCrossRefGoogle Scholar
- 5.The Committee of the Japan Children’s Cancer Registry. The Japan Children’s Cancer Registry: outline, results, and perspectives. In: Watanabe S, Tominaga S, Kakizoe T, editors. Cancer Treatment and survival. Tokyo: CRC Press; 1995.Google Scholar
- 12.Veerman AJ, Kamps WA, van den Berg H, van den Berg E, Bokkerink JP, Bruin MC, et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004). Lancet Oncol. 2009;10(10):957–66.PubMedCrossRefGoogle Scholar
- 15.Disease Registry Committee for the Japanese Society of Pediatric Hematology. Annual Report of Nationwide Survey 2008. Jpn J Pediatr Hematol. 2009;23:213–9.Google Scholar
- 16.Disease Registry Committee for the Japanese Society of Pediatric Hematology. Annual Report of Nationwide Survey 2009. Jpn J Pediatr Hematol. 2010;24:182–9.Google Scholar
- 17.Disease Registry Committee for the Japanese Society of Pediatric Hematology, Diagnostic guidelines for hematological diseases. Jpn J Pediatr Hematol. 2009;21 Suppl 5/6:1–76.Google Scholar
- 20.Coebergh JW, Reedijk AM, de Vries E, Martos C, Jakab Z, Steliarova-Foucher E, et al. Leukaemia incidence and survival in children and adolescents in Europe during 1978–1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42(13):2019–36.PubMedCrossRefGoogle Scholar
- 22.Amadori S, Testi AM, Arico M, Comelli A, Giuliano M, Madon E, et al. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group. J Clin Oncol. 1993;11(6):1046–54.PubMedGoogle Scholar
- 23.Webb DK, Harrison G, Stevens RF, Gibson BG, Hann IM, Wheatley K. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood. 2001;98(6):1714–20.PubMedCrossRefGoogle Scholar
- 24.Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood. 2001;97(1):56–62.PubMedCrossRefGoogle Scholar
- 25.Tsukimoto I, Tawa A, Horibe K, Tabuchi K, Kigasawa H, Tsuchida M, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009;27(24):4007–13.PubMedCrossRefGoogle Scholar
- 26.Imaizumi M, Tawa A, Hanada R, Tsuchida M, Tabuchi K, Kigasawa H, et al. Prospective study of a therapeutic regimen with all-trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia: the Japanese childhood acute myeloid leukaemia cooperative study. Br J Haematol. 2011;152(1):89–98.PubMedCrossRefGoogle Scholar
- 27.Kudo K, Kojima S, Tabuchi K, Yabe H, Tawa A, Imaizumi M, et al. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2007;25(34):5442–7.PubMedCrossRefGoogle Scholar
- 28.Imamura T, Iwamoto S, Kanai R, Shimada A, Terui K, Osugi Y, et al. Outcome in 146 patients with paediatric acute myeloid leukaemia treated according to the AML99 protocol in the period 2003–06 from the Japan Association of Childhood Leukaemia Study. Br J Haematol. 2012;159(2):204–10.PubMedCrossRefGoogle Scholar
- 33.Percy CL, Smith MA, Linet M, Gloeckler Ries LA, Friedman DL. Lymphoma and reticuloendothelial neoplasms. In: Ries LAG, Smith MA, Gurney JG, et.al., eds. Cancer incidence and survival among children and adolescents. United States SEER Program 1975–1995. Bethesda, MD: National Cancer Institute, SEER Program, 1999;35–49. Available at: http://www.acco.org/LinkClick.aspx?fileticket=CGsKkvHaH1Y%3D&tabid=670. Accessed November, 2012.
- 34.Fujita N, Kobayashi R, Takimoto T, Nakagawa A, Ueda K, Horibe K. Results of the Japan Association of Childhood Leukemia Study (JACLS) NHL-98 protocol for the treatment of B-cell non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia in childhood. Leuk Lymphoma. 2011;52(2):223–9.PubMedCrossRefGoogle Scholar